Free Trial

Climb Bio (CLYM) Competitors

Climb Bio logo
$1.26 0.00 (0.00%)
As of 07/8/2025 04:00 PM Eastern

CLYM vs. PRME, BNTC, HUMA, AMRN, AARD, AURA, HRTX, OLMA, AQST, and PRTA

Should you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Prime Medicine (PRME), Benitec Biopharma (BNTC), Humacyte (HUMA), Amarin (AMRN), Aardvark Therapeutics (AARD), Aura Biosciences (AURA), Heron Therapeutics (HRTX), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

Climb Bio vs. Its Competitors

Prime Medicine (NYSE:PRME) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Prime Medicine has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500.

Prime Medicine currently has a consensus price target of $10.08, suggesting a potential upside of 145.93%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 614.29%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Climb Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Climb Bio's return on equity of -43.95% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime MedicineN/A -107.87% -74.97%
Climb Bio N/A -43.95%-42.94%

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Comparatively, 3.2% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Climb Bio has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$3.85M139.97-$198.13M-$1.61-2.55
Climb BioN/AN/A-$73.90M-$2.38-0.53

In the previous week, Prime Medicine had 8 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Prime Medicine and 0 mentions for Climb Bio. Prime Medicine's average media sentiment score of 0.89 beat Climb Bio's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Prime Medicine Positive
Climb Bio Neutral

Summary

Prime Medicine beats Climb Bio on 8 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLYM vs. The Competition

MetricClimb BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$85.14M$2.87B$5.47B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-0.5320.8026.9920.11
Price / SalesN/A286.31428.71119.81
Price / CashN/A41.1936.8257.86
Price / Book0.407.487.985.56
Net Income-$73.90M-$55.04M$3.16B$248.40M
7 Day PerformanceN/A2.44%2.38%4.67%
1 Month Performance-5.97%1.90%2.17%6.64%
1 Year PerformanceN/A4.35%33.81%21.31%

Climb Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLYM
Climb Bio
2.6316 of 5 stars
$1.26
flat
$9.00
+614.3%
N/A$85.14MN/A-0.539Gap Up
PRME
Prime Medicine
4.0534 of 5 stars
$2.65
+9.5%
$10.08
+280.5%
-25.3%$347.93M$3.85M-1.29234Options Volume
BNTC
Benitec Biopharma
2.163 of 5 stars
$12.35
-6.2%
$23.83
+93.0%
+30.5%$345.46M$80K-8.1820Analyst Forecast
High Trading Volume
HUMA
Humacyte
2.749 of 5 stars
$2.22
+1.4%
$11.71
+427.7%
-54.7%$339.71M$1.57M-3.22150News Coverage
Gap Up
AMRN
Amarin
0.6044 of 5 stars
$15.90
-1.8%
$12.00
-24.5%
+13.8%$335.25M$228.61M-4.37360
AARD
Aardvark Therapeutics
N/A$13.86
-9.9%
$31.25
+125.5%
N/A$333.68MN/A0.0018
AURA
Aura Biosciences
1.8841 of 5 stars
$6.29
-4.3%
$22.00
+249.8%
-14.6%$330.27MN/A-3.3150Positive News
HRTX
Heron Therapeutics
3.8245 of 5 stars
$2.16
+0.5%
$5.00
+131.5%
-25.9%$328.01M$144.29M-36.00300Positive News
OLMA
Olema Pharmaceuticals
1.726 of 5 stars
$4.56
-4.0%
$24.50
+437.3%
-58.0%$325MN/A-2.2770Positive News
AQST
Aquestive Therapeutics
1.2446 of 5 stars
$3.25
flat
$10.14
+212.1%
+53.3%$322.82M$57.56M-5.51160
PRTA
Prothena
3.0445 of 5 stars
$6.18
+3.2%
$31.50
+409.7%
-67.7%$322.42M$135.16M-2.97130High Trading Volume

Related Companies and Tools


This page (NASDAQ:CLYM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners